The US has more than 9 million Johnson & Johnson doses ready to be administered now that federal health agencies have signed off on resuming the use of the one-shot vaccine, CNN has learned.
President Joe Biden’s coronavirus adviser Jeff Zients told CNN earlier Friday that quite 9 million doses had already been distributed to states, tribes, territories, and federal channels and were able to go once the panel recommended lifting the pause.
On Friday afternoon the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices — a panel that weighed whether to recommend a change in federal guidance on the vaccine — voted to recommend resuming use of the Johnson & Johnson vaccine for people 18 years and older. Members of the panel agreed the advantages of the vaccine outweigh the risks from rare blood clots linked with the vaccine.
Later Friday, the CDC and therefore the US Food and Drug Administration lifted their recommended pause on the utilization of the vaccine and said the label is going to be updated to point that ladies under 50 should remember the danger of blood clots. Earlier, Johnson & Johnson officials said that they had agreed to update the language for the label.
“I support the ACIP’s recommendation that the Johnson and Johnson COVID-19 vaccine be used for persons 18 years aged or older within us population under the FDA emergency use authorization, and that I have signed this recommendation,” CDC Director Dr. Rochelle Walensky said Friday.
The FDA will prepare an amended emergency use authorization for the vaccine, Dr. Amanda Cohn, ACIP’s secretary, told the panel.
On April 13, the FDA recommended pausing the administering of the one-dose Johnson & Johson coronavirus vaccine after six reported cases of girls who developed a rare blood coagulation syndrome after receiving the vaccine within us.
The CDC has learned of 15 cases of a rare blood coagulation condition called thrombocytopenia syndrome (or TTS) linked with Johnson & Johnson’s coronavirus vaccine, an expert told CDC vaccine advisers Friday.
All are among women, and 13 are in women under the age of fifty, the CDC’s Dr. Tom Shimabukuro told the panel. Three died, and 7 remain hospitalized.
So far, patients with TTS linked with Johnson & Johnson’s coronavirus vaccine have started showing symptoms one to 2 weeks after getting the vaccine, Shimabukuro said.
The risk translates to about seven cases of TTS per million doses of J&J vaccine given to women ages 18 to 49, Shimabukuro said, and slightly below 1 per million for ladies 50 and older.
“That doesn’t mean there’s no risk in males. There might be cases we didn’t identify within the database,” Shimabukuro said. “There might be cases that become apparent afterward that just haven’t appeared.”
Both the Johnson & Johnson and AstraZeneca Covid-19 vaccines appear to be setting off rare blood coagulation events during a few people that get them, but no blood clots are related to coronavirus vaccines made by Moderna or Pfizer, experts told the panel.
This story has been updated with additional developments Friday.